Hu C, Huang H, Na J, Lumby C, Abozaid M, Holdren M
Am J Hum Genet. 2024; 111(3):584-593.
PMID: 38417439
PMC: 10940015.
DOI: 10.1016/j.ajhg.2024.02.002.
Rein H, Bernstein K
DNA Repair (Amst). 2023; 130:103563.
PMID: 37651978
PMC: 10529980.
DOI: 10.1016/j.dnarep.2023.103563.
Torabi Dalivandan S, Plummer J, Gayther S
Cancers (Basel). 2021; 13(16).
PMID: 34439109
PMC: 8393346.
DOI: 10.3390/cancers13163953.
Andreassen P, Seo J, Wiek C, Hanenberg H
Genes (Basel). 2021; 12(7).
PMID: 34356050
PMC: 8307705.
DOI: 10.3390/genes12071034.
Jimenez-Sainz J, Jensen R
Genes (Basel). 2021; 12(5).
PMID: 34065235
PMC: 8161351.
DOI: 10.3390/genes12050780.
Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance.
Lee M, Shorthouse D, Mahen R, Hall B, Venkitaraman A
Nucleic Acids Res. 2021; 49(10):5588-5604.
PMID: 33978741
PMC: 8191791.
DOI: 10.1093/nar/gkab308.
Application of Multilayer Evidence for Annotation of C-Terminal Variants.
Butz H, Papp J, Bozsik A, Krokker L, Pocza T, Olah E
Cancers (Basel). 2021; 13(4).
PMID: 33672545
PMC: 7923782.
DOI: 10.3390/cancers13040881.
Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
Richardson M, Hu C, Lee K, LaDuca H, Fulk K, Durda K
Am J Hum Genet. 2021; 108(3):458-468.
PMID: 33609447
PMC: 8008494.
DOI: 10.1016/j.ajhg.2021.02.005.
K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review.
Baughan S, Tainsky M
Cancers (Basel). 2021; 13(3).
PMID: 33503928
PMC: 7865497.
DOI: 10.3390/cancers13030447.
Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Yoshida R, Hagio T, Kaneyasu T, Gotoh O, Osako T, Tanaka N
Cancer Sci. 2021; 112(3):1310-1319.
PMID: 33421217
PMC: 7935793.
DOI: 10.1111/cas.14803.
The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response.
Zhang Y, Park J, Zhang F, Olson S, Orlow I, Li Y
Hum Mutat. 2020; 42(2):150-163.
PMID: 33169439
PMC: 7997419.
DOI: 10.1002/humu.24133.
High-throughput functional evaluation of BRCA2 variants of unknown significance.
Ikegami M, Kohsaka S, Ueno T, Momozawa Y, Inoue S, Tamura K
Nat Commun. 2020; 11(1):2573.
PMID: 32444794
PMC: 7244490.
DOI: 10.1038/s41467-020-16141-8.
BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
Cifuentes-C L, Rivera-Herrera A, Barreto G
Colomb Med (Cali). 2020; 50(3):163-175.
PMID: 32284662
PMC: 7141151.
DOI: 10.25100/cm.v50i3.2385.
Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers.
Federici G, Soddu S
J Exp Clin Cancer Res. 2020; 39(1):46.
PMID: 32127026
PMC: 7055088.
DOI: 10.1186/s13046-020-01554-6.
Novel RNA and DNA strand exchange activity of the PALB2 DNA binding domain and its critical role for DNA repair in cells.
Deveryshetty J, Peterlini T, Ryzhikov M, Brahiti N, Dellaire G, Masson J
Elife. 2019; 8.
PMID: 31017574
PMC: 6533086.
DOI: 10.7554/eLife.44063.
The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination.
Zhao W, Wiese C, Kwon Y, Hromas R, Sung P
Annu Rev Biochem. 2019; 88:221-245.
PMID: 30917004
PMC: 7004434.
DOI: 10.1146/annurev-biochem-013118-111058.
Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer.
Willoughby A, Andreassen P, Toland A
J Pers Med. 2019; 9(1).
PMID: 30832243
PMC: 6462925.
DOI: 10.3390/jpm9010015.
GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes.
Caleca L, Colombo M, Hansen T, Lazaro C, Manoukian S, Parsons M
Cancers (Basel). 2019; 11(2).
PMID: 30696104
PMC: 6406614.
DOI: 10.3390/cancers11020151.
Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing.
Heczkova M, Machackova E, Macinga P, Gallmeier E, Cahova M, Spicak J
Cancer Biol Ther. 2019; 20(5):633-641.
PMID: 30638113
PMC: 6606029.
DOI: 10.1080/15384047.2018.1550566.
Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandao R, Mensaert K, Lopez-Perolio I, Tserpelis D, Xenakis M, Lattimore V
Int J Cancer. 2019; 145(2):401-414.
PMID: 30623411
PMC: 6635756.
DOI: 10.1002/ijc.32114.